Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization~* At least one of the following signs or symptoms of bacteremia:~  1. fever (e.g.≥ 38 °C/100.4 °F measured orally)~ 2. white blood cell count \> 10,000 or \< 4,000 cells/µL, or \> 10% immature neutrophils (bands)~ 3. tachycardia (heart rate \> 90 bpm)~ 4. hypotension (systolic blood pressure \< 90 mmHg)~* At least one of the following:~  1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis~ 2. Persistent SAB~ 3. Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria~ 4. Other forms of complicated SAB~ 5. Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)~ 6. Epidural or cerebral abscess~* Other inclusion criteria have been applied~Exclusion Criteria:~* Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance~* Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam~* Left-sided infective endocarditis~* Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices~* Community- or hospital-acquired pneumonia~* Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active~* Requirement for continuous renal-replacement therapy~* Women who are pregnant or nursing~* Other exclusion criteria have been applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)
- Daptomycin (Type: ACTIVE_COMPARATOR): Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam

Based on this trial design, predict the completion outcome and termination type (if applicable).